Pharmaceuticals

A new strategic alliance brings European cGMP-grade vitamin APIs to the U.S., promising to enhance quality and supply reliability for compounding pharmacies.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

Former Trade Desk CMO Ian Colley joins DeepIntent, signaling an aggressive push into AI-powered marketing for the specialized healthcare advertising sector.

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

As BioPharma races to adopt AI, fragmented data remains a huge hurdle. A Boston forum aims to find solutions for building a trusted digital foundation.

For the 8th straight year, Equashield dominates the CSTD market. We explore the tech, trust, and automation driving its success in protecting workers.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.

A three-month FDA delay for a new LEQEMBI injection highlights the high-stakes race for a convenient Alzheimer's therapy and its complex safety hurdles.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

Aptar Pharma and the FDA lead a critical mission to reinvent respiratory medicine, ensuring patient safety while tackling the climate impact of inhalers.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.